Cardio-vascular
Refine Search
Pharmaceutical
Anglo-Swedish company AstraZeneca will present additional evidence of cardiovascular (CV) benefits associated with longer-term use of Brilinta (ticagrelor) at the European Society of Cardiology (ESC) Congress 2017. 24 August 2017
Biotechnology
San Franciscan firm Cytokinetics is pursuing an unusual angle to therapeutic discovery, starting from an understanding of the biology of muscles in order to explore treatment options in different disease areas. 22 August 2017
Biotechnology
OptiBiotix Health has expanded the terms of a manufacturing, supply and profit sharing deal agreed with Italy’s Sacco and announced in March. 22 August 2017
Biotechnology
Phase III results published in the New England Journal of Medicine (NEJM) have shown that lowering LDL cholesterol levels with Repatha (evolocumab) does not impair cognition. 17 August 2017
Pharmaceutical
A new coagulation reversal agen, Praxbind (idarucizumab) from German family-owned pharmaceutical company Boehringer Ingelheim, is now being used in Brazil, following marketing clearance earlier this year. 17 August 2017
Pharmaceutical
How the USA views the UK’s state reimbursement came up for comment last week, following the recent approval by the National Institute for Health and Care Excellence (NICE) of Eli Lilly’s cancer drug Lartruvo. Also attracting attention were MyoKardia’s heart drug mavacamten, Valeant Pharmaceutical International not getting US approval for its eye drug candidate latanoprostene bunod, and Demira’s acquisition of Roche cast-off lebrikizumab, a dermatology candidate. 13 August 2017
Pharmaceutical
Improvements in patient care in the UK mean hundreds more people are surviving heart failure, a new independent study has found. 11 August 2017
Biotechnology
Shares of US biotech firm MyoKardia soared 83.38% to $31.45 by close of trading on Monday, after the company announced positive mid-stage results with its mavacamten, formerly known as MYK-461. 8 August 2017
Pharmaceutical
Daiichi Sankyo revealed this morning that it has signed an investment contract with Cuorips Inc, an Osaka University spin-off venture to receive an option right concerning the worldwide commercialization of iPS-derived cardiomyocyte (iPS-CM) sheet developed by Cuorips. 7 August 2017
Biotechnology
Japan's largest pharma company, Takeda Pharmaceutical, has announced two deals with USA-based biotech firms in as many days. 4 August 2017
article
Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24% to 9.2 billion euros ($10.86 billion) on the same period in the previous year after adjustment for currency effects (+27% in euro terms). 2 August 2017
Pharmaceutical
Japanese pharma major Daiichi Sankyo (TYO: 4568) and its US subsidiary have agreed to enter into a program to settle, on behalf of all defendants, pending product liability litigation against various Daiichi Sankyo and Forest entities. 2 August 2017
Pharmaceutical
The European Commission has approved an update to the Victoza (liraglutide) label in the European Union that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. 28 July 2017
Pharmaceutical
Italian drugmaker Recordati has posted a strong set of financial results for the first half of 2017, underlining the continued growth of the group, with revenues and profitability increasing significantly. 28 July 2017
Pharmaceutical
So far as investors are concerned, news from across the Atlantic has overshadowed a set of quarterly financial results from US pharma major Bristol-Myers Squibb that met or beat analyst expectations. 27 July 2017
Pharmaceutical
AstraZeneca suffered a fierce blow on Thursday with the announcement of the failure of its high-profile lung cancer trial Mystic to meet a primary endpoint in initial results, and its second quarter financial results, presented on the same day, did not offer much encouragement for the future either. 27 July 2017
Pharmaceutical
Reduced growth forecasts at German life sciences group Bayer hit the company’s stocks hard on Wednesday morning, with its share price sliding by 3% to 108.65 euros in three hours after the announcement of the latest quarterly financials. 27 July 2017
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) – has published a final standard, which aims to improve the assessment and management of chronic kidney disease (CKD) in adults. 27 July 2017
Generics
Baxter International and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle Federal Trade Commission charges that Baxter’s proposed $625 million acquisition of Claris Injectables business of the Indian parent company is anticompetitive. 21 July 2017
Biotechnology
Final results from the RE-VERSE AD study show that idarucizumab, marketed in the USA as Praxbind, was able to immediately reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients in emergency situations. 12 July 2017
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze